SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community discusses potential price movements and upcoming catalysts, like a possible Solana ETF. Community members are focused on phrases like "WAGMI" and speculate on $200+ targets. There's also discussion around various Solana-based meme coins gaining traction.

Pump.fun

$PUMP is gaining attention, with community members actively buying and expressing enthusiasm. Much of the discussion revolves around the $SOL ecosystem and the sentiment that 'We Are All Gonna Make It' ($WAGMI). Some users believe $PUMP has the potential for significant growth, drawing comparisons to other successful tokens.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as community members highlight its resilience and stable market capitalization within the Solana ecosystem. Talk centers on the token's potential for significant revaluation, driven by strong holder growth and expanding visibility. The community emphasizes a long-term vision, focusing on building and holding.

The 401jk (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and also the 401k. The 401k total holdings are valued at around $12 trillion USD and it is the most popular retirement savings plan in the US. As time passes forevermore true retirement, or as we like to call it real freedom will only become much harder and harder for people to attain.  Through meme fueled laser focus and cyperphunk ideology the 401jK meme retirement fund token and community aim to point out the absurdities of how rigged our current system is, and how only insiders and those with power are starting the benefit from the increased centralization of cryptocurrency.........while also aiming to flip the $12 trillion USD 401k system to achieve freedom before our backs and knees are breaking.

401jK

$401JK is trending due to its community's focus on challenging traditional retirement systems and promoting the idea of financial freedom through crypto. Community members are actively discussing the token's potential to disrupt conventional 401(k) plans and create a new path to early retirement, emphasizing its strong community and organic growth on the Solana blockchain.

Trump For President

The $TRUMP crypto token is trending amid renewed focus on political hype coins, spurred by recent poll headlines, leading to increased volatility. The community's discussion varies wildly, ranging from strong support tied to the 'MAGA' movement and the upcoming election to harsh criticism, including accusations of being a 'creepy PEDO cult stock' or a 'scam'. Additionally, potential consensus between U.S. and China officials regarding rare earth elements and tariffs, involving Trump and Xi, may also be contributing to the current interest.

Shibmas was launched on the 9th Of December. The project is a meme token and gives homage to Shiba Inu the token. The token is a playful character who is bringing the Christmas spirit to token holders all around the world. We plan on getting many listings on various exchanges in the coming days. We have over 1000 holders in 24 hours and we aim on getting over 10000 holders within the next week and in the run up to Christmas

Shibmas

Shibmas ($SMAS) is trending amid community excitement and positive sentiment, particularly within the Phantom Wallet ecosystem. Discussions highlight its clean chart, potential for a breakout, and steady price action, with many noting the 'bullish vibes' and 'rocket energy' surrounding the crypto. The community is closely watching for increased volume and a catalyst to propel the price higher.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as the community rallies around its fair launch and strong performance compared to other meme coins. Discussion focuses on its unique position as a Bitcoin-native meme, contrasting it with alternatives and celebrating its resilient community. Some are speculating about potential listings on major exchanges.

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Avidity Biosciences Inc

Avidity Biosciences ($RNA) is trending amid speculation of a potential acquisition, with community members highlighting positive trial data and a strong cash position. The stock is seeing increased interest and unusual options activity, leading to discussions about a possible buyout by Novartis ($NVS) or other major pharmaceutical players. Despite some skepticism and recent insider selling, many investors remain bullish, citing analyst price targets and the potential for significant gains in the muscular dystrophy treatment space.

Citizens Financial Group, Inc. engages in the provision of commercial banking services. It operates through the Consumer Banking and Commercial Banking segments. The Consumer Banking segment includes deposit products, mortgage and home equity lending, student loans, auto financing, credit cards, business loans, and wealth management and investment services. The Commercial Banking segment offers lending and leasing, trade financing, deposit and treasury management, foreign exchange and interest rate risk management, corporate finance and debt, and equity capital markets. The company was founded in 1828 and is headquartered in Providence, RI.

Citizens Financial Group Inc

Citizens Financial Group ($CFG) is trending due to a mix of factors, including recent Q3 earnings reports exceeding expectations and a raised dividend. Community discussion centers on the bank's financial health and whether this momentum can continue. Analyst ratings have been updated, with some highlighting upside potential alongside general optimism for the banking sector, specifically regional banks.

Clanker is an autonomous agent for deploying tokens. Currently, users may request clanker to deploy an ERC-20 token on Base by tagging it @clanker on Farcaster.

tokenbot

Tokenbot ($CLANKER) is trending due to a recent acquisition by Farcaster, a decentralized social network, which the community believes will boost its utility and value. The token's small circulating supply and aggressive buyback mechanism are also fueling discussions around potential for significant price movement. Some users are wary of a potential rug pull, while others point to strong revenue generation and exchange listings as bullish signals.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ocular Therapeutix (OCUL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Ocular Therapeutix (OCUL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -11.43% and -0.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?

Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Shares of Ocular Therapeutix (OCUL) plunged nearly 17% on Monday, marking their steepest single-day decline since April, as the biotech firm's fourth-quarter earnings missed expectations. The stock extended losses in after-hours trading.The company posted Q4 revenue of $17.08 million, slightly below analysts' estimates of $17.16 million. While its quarterly loss narrowed to $0.29 per share from $0.35 a year earlier, it still came in wider than the Street's forecast of $0.27 per share.Ocular also announced a delay in releasing late-stage trial data for axpaxli, its experimental treatment for wet age-related macular degeneration (wet AMD), shifting the timeline from Q4 2025 to Q1 2026. The adjustment follows FDA approval of study protocol changes under a Special Protocol Agreement (SPA).Despite the earnings disappointment and trial delay, Ocular reaffirmed its financial stability, reporting a cash balance of $392.1 million as of Dec. 31, 2024, which it expects to fund operations into 2028 without the need for additional capital raises this year.Retail sentiment on Stocktwits flipped to 'bullish' from 'bearish' amid the sell-off, with message volume surging 2,200% by the end of Monday's regular session.<figure class="image"><img style="aspect-ratio:1316/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/OCUL_sentiment_and_message_meter_as_of_March_3_4b0b51c1ff.png" alt="OCUL sentiment and message meter as of March 3.png" width="1316" height="316"><figcaption>OCUL sentiment and message meter as of March 3 | source: Stocktwits</figcaption></figure>One trader argued that selling the stock now could mean missing a long-term payoff, setting a personal price target of $25 — implying a potential 500% upside from the last close.&nbsp;<stembedurl>https://stocktwits.com/WaterskiUP/message/606602356</stembedurl>Another investor expressed optimism but questioned why the company didn't provide updated enrollment figures for its SOL-R (Phase 3, wet AMD) trial or 2025 revenue guidance for Dextenza, an FDA-approved corticosteroid for post-surgical inflammation and allergic conjunctivitis.<stembedurl>https://stocktwits.com/esu89/message/606599224</stembedurl>Ocular modified its SOL-R trial protocol, reducing the number of randomized subjects from 825 to 555, citing "strong" ongoing enrollment. As of Jan. 10, 2025, 311 subjects had been enrolled across various stages in the U.S. and South America.<a href="https://stocktwits.com/symbol/OCUL">OCUL stock</a> has tumbled more than 31% year-to-date.&nbsp;Wall Street analysts remain bullish — of the nine analysts covering the stock, five rate it a 'Buy,' while four call it a 'Strong Buy,' according to Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of stock price falling.

Ocular Therapeutix Stock Sees Worst Day In Nearly A Year On Q4 Miss, But Retail Sees A Comeback

The company also announced a delay in releasing late-stage trial data for axpaxli, its experimental treatment for wet AMD, shifting the timeline from Q4 2025 to Q1 2026.

Equity

Optimistic Buy Rating for Ocular Therapeutix Amid Promising Axpaxli Trials and Strategic Execution

In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Ocular Therapeutix (OCUL Research Report), with a pr...

Shares of 4D Molecular Therapeutics Inc. (FDMT) plummeted over 35% to $17.30 by Wednesday afternoon, marking it as the top loser among U.S. stocks. Surprisingly, retail traders remain highly bullish on the stock, with Stocktwits sentiment extremely bullish (85/100) amid extremely high message volumes (95/100).<figure class="image"><img style="aspect-ratio:1308/308;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/FDMT_Sentiment_Meter_On_Jul_17_5f2f85024d.png" alt="FDMT Stocktwits Sentiment Meter On Jul 17" width="1308" height="308"><figcaption>FDMT Stocktwits Sentiment Meter On Jul 17</figcaption></figure>Initially, FDMT shares climbed following the release of encouraging mid-stage clinical study results for its 4D-150 gene therapy, aimed at treating wet age-related macular degeneration (wAMD), a chronic eye disorder that leads to blurred vision or blind spots in central vision.However, the broader market turned its focus to various downside risks, including safety concerns raised by RBC Capital. While the firm maintains 4D-150 is "best in class," it flagged a "safety blip" – one case of inflammation in a patient with a history of syphilis, Investing.com <a href="https://in.investing.com/news/stock-market-news/4d-molecular-therapeutics-tumbles-following-midstage-clinical-study-results-432SI-4316187">reported</a>. BMO Capital lowering the price target further may have added to the pressure.Despite the sell-off, retail investors on Stocktwits seem to view Wednesday’s crash as a buying opportunity. One user noted that 4D’s peers, Ocular Therapeutix Inc. (OCUL), Adverum Biotechnologies Inc (ADVM) and EyePoint Pharmaceuticals Inc. (EYPT), “are taking it on the chin today.”“Obviously, Nasdaq taking it hard today as well. &nbsp;Perhaps, just a general opinion of overvaluation and market fatigue? &nbsp;Very odd stock movement to me, I do expect it will reverse soon,” said Stocktwits user ‘<a href="https://stocktwits.com/ehschunk/message/579821570">ehschunk</a>’.<figure class="image"><img style="aspect-ratio:1318/454;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/FDMT_stocktwits_comment_Jul_17_88b7f49b68.png" alt="Stocktwits user ehschunk's post on FDMT stream" width="1318" height="454"><figcaption>Stocktwits user ehschunk's post on FDMT stream</figcaption></figure>The overall market sentiment didn’t help, as U.S. stocks pulled back from their all-time highs on Wednesday, impacted by falling chip and tech stocks, though the Dow Jones managed its sixth consecutive day of gains.FDMT shares are down over 19% year-to-date, contrasting with OCUL’s impressive 65% rise. EYPT has had an even tougher year, losing 57% so far, while ADVM has lost only 0.18%.However, FDMT’s consistent performance in beating EPS estimates for the past four quarters provides some relief and hope for a rebound among its retail investors.

Wall Street’s Top Loser Today Stays In Retail’s Good Books: Stocktwits Extremely Bullish On FDMT

Despite a 35% drop in shares, retail investors remain bullish on 4D Molecular Therapeutics

Wall Street’s Top Loser Today Remains In Retail’s Good Books

Despite a 35% drop in shares, retail investors remain bullish on 4D Molecular Therapeutics on promising clinical study results

Piper Sandler Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)

Piper Sandler analyst Biren Amin maintained a Buy rating on Ocular Therapeutix (OCUL Research Report) today and set a price target of $15.00. The...

US Stocks At All-Time High, Nasdaq Futures Gains For 8th Day After SNB Unexpectedly Cuts Rate

US Stocks At All-Time High, Nasdaq Futures Gains For 8th Day After SNB Unexpectedly Cuts Rate

 After hitting the beach during yesterday's blistering Juneteenth holiday, the "buy...

Deep Dive Into Ocular Therapeutix Stock: Analyst Perspectives (6 Ratings)

Latest Ratings for OCUL
 DateFirmActionFromTo Mar 2022JMP SecuritiesMaintainsMarket Outperform Nov 2021JMP SecuritiesMaintainsMarket Outperform Oct 2021HC Wainwright & Co.MaintainsBuy
 View More...

Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder

Ocular Therapeutix's Phase 1 HELIOS study unveils Axpaxli's efficacy in treating non-proliferative diabetic retinopathy. Significant DRSS improvement with no worsening observed. Positive Phase 2 data...

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

OCUL
Ocular Therapeutix Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OCUL News

OCULOcular Therapeutix Inc